Alpha Tau Medical Ltd.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsAlpha Tau Medical Ltd. is a clinical-stage Israeli developer of the Alpha DaRT alpha-radiation cancer therapy, listed on Nasdaq with no approved commercial product as of fiscal 2025.
What they do
Alpha Tau Medical Ltd. develops Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), a proprietary alpha-radiation cancer treatment. The company's operations are primarily research and development focused, with clinical trials underway globally. It has not reported any product revenue in its latest annual filing, reflecting its pre-commercial stage.
Revenue drivers
- Alpha DaRT therapy — The sole pipeline product; no revenue has been reported from 2021 through 2025, as the company remains pre-commercial.
Recent performance
Net loss widened to $42.6M in 2025 from $31.8M in 2024, with diluted EPS at $-0.53. Operating cash flow was negative $26.7M in 2025, worsening from negative $19.8M in 2024. The company held $12.2M in cash and equivalents at December 31, 2025, against total assets of $105.7M and equity of $77.1M. No revenue was generated in any reported period.
Strategy
Management's stated direction is advancing the Alpha DaRT clinical development program toward regulatory approval, building on prior trials. The company continues to invest in R&D, as reflected in rising net losses and cash burn. It maintains an organizational structure with Israeli headquarters and Nasdaq-listed securities (DRTS, DRTSW).
Risks
- Pre-revenue clinical stage — The company has no approved product or product revenue, with cumulative net losses exceeding $160M from 2021 through 2025.
- Cash runway — Cash of $12.2M at end-2025 against a 2025 operating cash outflow of $26.7M implies limited runway absent new financing.
- Clinical trial failure — Alpha DaRT's ability to gain marketing approval hinges on successful completion and regulatory review of ongoing clinical trials, which may fail.
- Foreign jurisdiction exposure — Incorporated in Israel with operations abroad, subject to geopolitical, currency, and regulatory risks distinct from US-based peers.
Outlook
Management has not provided explicit forward guidance in the filing. Near-term priorities center on continued R&D spending, advancing clinical milestones, and securing additional capital to fund operations. The absence of revenue and elevated cash consumption point to a financing-dependent outlook.